Prior exposure to rosuvastatin 20 mg was associated with a reduced risk of DVT recurrence or post-thrombotic syndrome compared to no statin (HR 0.67; 95% CI 0.50-0.90; P=0.008).
Cohort (n=255)
Does rosuvastatin reduce DVT recurrence and/or post-thrombotic syndrome in patients with deep vein thrombosis?
Rosuvastatin use prior to DVT diagnosis is associated with a dose-dependent reduction in DVT recurrence and post-thrombotic syndrome.
Hazard Ratio: 0.67 (95% CI 0.5–0.9)
Absolute Event Rate: 31.8% vs 47.1%
p-value: p=0.008
BACKGROUND: Deep vein thrombosis (DVT) remains associated with substantial morbidity despite anticoagulation therapy, with 20-30% experiencing recurrence and up to 50% developing post-thrombotic syndrome (PTS). Statins possess anti-inflammatory properties that may benefit DVT outcomes, but evidence for adjunctive use remains limited. METHODS: , 2024. Using multinomial propensity scores, we matched patients 1:1:1 who were receiving rosuvastatin 20 mg (N.=85), rosuvastatin 10 mg (N.=85), or no statin (N.=85) for ≥3 months before DVT diagnosis. All patients received guideline-directed anticoagulation. Primary outcome was composite of DVT recurrence and/or PTS. We used Cox regression for time-to-event analyses and mixed-effects models for biomarker trajectories. RESULTS: After median follow-up of 42 months (IQR 36-48), the primary outcome occurred in 31.8% of rosuvastatin 20-mg group, 38.8% of 10-mg group, and 47.1% of controls (HR=0.67, 95% CI 0.50-0.90, P=0.008 for 20 mg vs. control). Both rosuvastatin groups showed greater reductions in inflammatory markers compared to controls. Complete vein recanalization at 48 months was observed in 74.1%, 65.9%, and 58.8% respectively (overall P=0.045; pairwise 20 mg vs. control P=0.095, Table II). Safety profiles were similar across groups, with no excess bleeding or muscle-related events. CONCLUSIONS: In this hypothesis-generating study, rosuvastatin use was associated with reduced DVT complications, with suggestions of dose-dependent effects. These associations require confirmation in prospective randomized trials before clinical recommendations can be made.
Nikolić et al. (Mon,) conducted a cohort in Deep vein thrombosis (DVT) (n=255). Rosuvastatin vs. No statin was evaluated on Composite of DVT recurrence and/or PTS (HR 0.67, 95% CI 0.50-0.90, p=0.008). Prior exposure to rosuvastatin 20 mg was associated with a reduced risk of DVT recurrence or post-thrombotic syndrome compared to no statin (HR 0.67; 95% CI 0.50-0.90; P=0.008).